cbdMD Reports 20% Revenue Growth to $5.6 Million in Q3 Fiscal 2026

cbdMD, Inc. reported its financial results for the third quarter of fiscal 2026, revealing a total net sales figure of $5.6 million, a 20% increase from $4.6 million in the same period last year. For the nine months ending June 30, 2026, the company achieved net sales of $16.2 million, up 12% from $14.5 million in the prior year. Despite this growth, the company recorded a net loss of $1.2 million for the quarter and $2.4 million for the nine-month period, although this represented an improvement compared to the net loss of $1.3 million and $3.7 million for the respective periods in the previous year.

The company’s cost of sales increased to $2.5 million for the quarter, up from $1.8 million, reflecting a shift in sales mix towards wholesale business and increased warehouse labor costs. Operating expenses also rose to $4.2 million from $3.7 million year-over-year, driven by higher payroll costs associated with the recent acquisition of Bluebird Botanicals and increased professional service fees. The gross profit margin decreased to 54.7% from 61.5% in the prior year, attributed to the rising costs associated with sales and operations.

Strategically, cbdMD completed the acquisition of Bluebird Botanicals in January 2026, which is expected to enhance its product offerings and customer base. The acquisition involved issuing 425,000 shares of restricted common stock and could include an additional 525,000 shares based on performance metrics. This move is part of the company's broader strategy to diversify its revenue streams and mitigate risks associated with regulatory changes in the hemp industry. The integration of Bluebird is anticipated to yield significant synergies, although it has also incurred additional costs impacting short-term profitability.

Operationally, cbdMD has seen a shift in its sales channels, with e-commerce sales contributing 70.2% of total net sales in the latest quarter, while wholesale sales accounted for 29.8%. The company is actively pursuing further acquisitions and has invested in marketing initiatives to enhance customer acquisition. However, it faces challenges from evolving regulatory frameworks, particularly concerning THC limits in hemp-derived products, which could impact future revenue. The company is preparing for potential changes in legislation and is exploring product reformulation and channel diversification as part of its risk management strategy.

Looking ahead, cbdMD remains focused on achieving profitability and improving its financial position. The company has implemented cost-saving measures aimed at reducing monthly expenses by $100,000 to $150,000, which could translate to annual savings of up to $1.8 million. Despite the challenges posed by regulatory uncertainties, cbdMD is optimistic about its growth trajectory, bolstered by its recent acquisition and ongoing product innovation efforts. The company continues to evaluate its strategic options to navigate the changing landscape of the hemp industry effectively.